Why the study?
Does early appearance of neutralizing IgG3 antibodies improve viral clearance and prevent persistent arthralgia in CHIKV-infected patients?
Does early appearance of neutralizing IgG3 antibodies improve viral clearance and prevent persistent arthralgia in CHIKV-infected patients?
The absence of early CHIKV-specific IgG3 antibodies may serve as a biomarker for patients at increased risk of persistent arthralgia following Chikungunya infection.
No takes yet. Share an insight, caveat, or question.
May flag CHIKV patients for arthralgia monitoring; leaves open whether IgG3 kinetics can guide interventions.
Kam et al. (2012) studied this question.